The Plk1 Inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy In Vitro

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Lu, Bo ^a   Mahmud, Hasan ^a   Maass, Alexander H ^a   Yu, Bo ^b   van Gilst, Wiek H ^a   de Boer, Rudolf A ^a   Silljé, Herman H W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ENDOTHELIN 1; PHENYLEPHRINE; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO LIKE KINASE 1; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ANEUPLOIDY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTERPHASE; MITOSIS INHIBITION; NEWBORN; NONHUMAN; NUCLEAR SIZE; RAT; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HEART; HEART MUSCLE; HELA CELL; MITOSIS; SPRAGUE DAWLEY RAT;

RATTUS;

ANEUPLOIDY; ANIMALS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLASTS; HEART; HELA CELLS; HUMANS; MITOSIS; MYOCARDIUM; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77958574408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012963     Document Type: Article

References (33)

1. Maass AH, Buvoli M (2007) Cardiomyocyte preparation, culture, and gene transfer. Methods Mol Biol 366: 321-330.
2. Ren D, Miller JD (2003) Primary cell culture of suprachiasmatic nucleus. Brain Res Bull 61: 547-553.
3. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, et al. (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of pololike kinase 1. Curr Bio 17: 304-315.
4. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322.
5. Barr FA, Sillje HH, Nigg EA (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440.
6. van de Weerdt BC, Medema RH (2006) Polo-like kinases: a team in control of the division. Cell Cycle 5: 853-864.
7. Elia EA, Cantley LC, Yaffe MB (2003) Proteomic screen finds pSer/pThrbinding domain localizing Plk1 to mitotic substrates. Science 299: 1228-1231.
8. Elia EA, Rellos P, Haire LF, Chao JW, Ivins FJ, et al. (2003) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115: 83-95.
9. Hanisch A, Wehner A, Nigg EA, Sillje HH (2006) Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 17: 448-459.
10. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, et al. (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26: 2262-2273.
11. Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135: 1701-1713.
12. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, et al. (2003) Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 22: 69-80.
13. Liu X, Lei M, Erikson RL (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093-2108.
14. an Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, et al. (2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 279: 36841-36854.
15. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877.
16. Santamaria A, Neef R, Eberspacher U, Eis K, Husemann M, et al. (2007) Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 18: 4024-4036.
17. Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cance 6: 321-330.
18. van Vugt MA, Bras A, Medema RH (2004) Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 15: 799-811.
19. Kumagai A, Dunphy WG (1996) Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273: 1377-1380.
20. Nakajima H, Toyoshima-Morimoto F, Taniguchi E, Nishida E (2003) Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 278: 25277-25280.
21. Okano-Uchida T, Okumura E, Iwashita M, Yoshida H, Tachibana K, et al. (2003) Distinct regulators for Plk1 activation in starfish meiotic and early embryonic cycles. EMBO J 22: 5633-5642.
22. Schoffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570.
23. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, et al. (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26: 5511-5517.
24. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, et al. (2010) Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer.
25. Maass A, Langer SJ, Oberdorf-Maass S, Bauer S, Neyses L, et al. (2003) Rational promoter selection for gene transfer into cardiac cells. J Mol Cell Cardiol 35: 823-831.
26. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, et al. (2010) Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A. Arterioscler Thromb Vasc Biol 30: 1407-1414.
27. Schraa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, et al. (2002) Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J Control Release 83: 241-251.
28. Maass A, Grohe C, Kubisch C, Wollnik B, Vetter H, et al. (1995) Hormonal induction of an immediate-early gene response in myogenic cell lines-a paradigm for heart growth. Eur Heart J 16 (Suppl C: 12-4): 12-14.
29. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589.
30. Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358: 1370-1380.
31. Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785.
32. Brito DA, Rieder CL (2009) The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE- 1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton 66: 437-447.
33. Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432: 338-341.